5/73
  • Pages
  • Editions
01 Cover
02 Welcome Letter / Sections
03 Article & Interview Directory
04 Section 1: Introduction
05 Introduction to US Life Sciences
06 Janssen Pharmaceuticals Interview
07 Investment Climate
08 MPM Capital Interview
09 Signet Healthcare Partners Interview
10 Xontogeny Interview
11 Insights from EisnerAmper
12 The Life Sciences Regulatory Climate
13 Buchanan Ingersoll & Rooney PC Interview
14 PhRMA Interview
15 PBOA Interview
16 Ernst & Young LLP Interview
17 LaVoieHealthScience Interview
18 Section 2: Introducing the Hubs
19 East Coast
20 BioNJ Interview
21 MassBio Interview
22 Pennsylvania Biotechnology Center Interview
23 West Coast
24 Biocom California Interview
25 QB3-Berkeley Interview
26 Section 3: Drug Discovery and Development
27 Therapeutic Fields On Fire
28 Insmed Interview
29 Mammoth Biosciences Interview
30 Innovations Enhancing the Patient Experience
31 Arcturus Therapeutics Interview
32 Karius Interview
33 Expert Insights: Targeted Therapeutics
34 First Wave BioPharma Interview
35 Aphios Corporation Interview
36 Section 4: Contract Manufacturing and Chemicals
37 A Shifting Landscape
38 Syngene International Interview
39 Cambrex Interview
40 Lubrizol Life Science Interview
41 Aenova Group Interview
42 Keeping Up With Demands
43 Cureline Interview
44 Interview: Murli Krishna Pharma
45 PsychoGenics Interview
46 Expert Insights: Innovative Technologies
47 AMPAC Fine Chemicals Interview
48 TCG Lifesciences Interview
49 CordenPharma Interview
50 Quotient Sciences Interview
51 A Post-Pandemic World
52 New Vision Pharmaceuticals Interview
53 Adare Pharma Solutions Interview
54 Ascendia Pharmaceuticals Interview
55 Chemicals Producers and Distributors
56 Brenntag North America Interview
57 BASF Pharma Solutions Interview
58 Section 5: Technology Services
59 Life Sciences Go Digital
60 RxS Interview
61 Insights from Markem-Imaje
62 AiCure Interview
63 WhizAI Interview
64 Section 6: Company Profiles
65 Brenntag Company Profile
66 Adare Pharma Solutions Company Profile
67 Quotient Sciences Company Profile
68 SK pharmteco Company Profile
69 AiCure Company Profile
70 Markem-Imaje Company Profile
71 TCG Lifesciences Company Profile
72 Murli Krishna Pharma Company Profile
73 Credits

Introduction

The end of an era?

The achievements of the life sciences industry over the past two years have been nothing short of astounding. In a previously unimaginably short time frame, the sector developed and produced multiple Covid-19 vaccines that were effectively distributed to billions of people across the globe. Simultaneously, revolutionary therapies to curb the severity of infection and a host of new diagnostics tools were introduced.

Rather than celebrating a singular entity – whether it be a pharma or biotech company, a research institution, or even an administration – it is instead a particular ethos that carried the day: the willingness to collaborate. A DNA map of the virus was distributed around the world to enable efficient collaboration in discovering vaccines. According to Anne Pritchett of PhRMA, voluntary partnerships around the world led to over 370 collaborations for Covid-19 vaccine manufacturing and 155 for therapeutics, including longstanding intellectual property protections and voluntary technology transfers. Partnerships between industries and governments were also significant: The US government invested US$13 billion into the development of vaccines, and the FDA accelerated its regulatory review process without sacrificing quality to meet the emergency.

Yet the driver of this collaboration was a common enemy: the Covid-19 virus. As such, the question presents itself: once the pandemic is over, will everybody go home?

“The experience has made some people wonder what it would look like if the industry came together to solve cancer in the same way it came together around Covid-19, but science is not simple, and collaboration is even harder.”

Juliet Hart, CEO & Founder, Hart & Chin

Juliet Hart, CEO and founder of Hart & Chin, believes this will be the case. “Once this period is over, companies will no longer be unified by the same goal, and competition will resume,” Hart predicts. “The experience has made some people wonder what it would look like if the industry came together to solve cancer in the same way it came together around Covid-19, but science is not simple and collaboration is even harder.”

Nevertheless, the past two years have created and strengthened bonds between unlikely actors who may not be so quick to forget what they can achieve when working together. While collaboration may be challenging, this period has proven that life sciences companies are more than up to the task. That is not a lesson that will likely be so quickly unlearned.

The popularity of the life sciences

Covid-19 presented a much-needed facelift to the reputation of the life sciences industry. Public opinion reached an all-time high, as people witnessed for the first time in recent history what it is like to live with a global unmet medical need. As vaccines flew through the development and regulatory processes, the public watched with a keen interest, and in doing so, learned about the groundbreaking achievements being made in fields such as mRNA technology.

In the US, there has historically been a pervading sentiment that pharmaceutical companies are overly profit-driven. The pandemic gave these companies a platform to prove otherwise. AstraZeneca, for example, was not even in the vaccine business before the start of the pandemic. That did not stop their executive leaders from making a decision to pour resources into developing a Covid-19 vaccine, aware that the global need had to be addressed immediately. If leading pharma and biotech companies did not step up, who would? This level of altruism from a public company allowed them, if only momentarily, to shift from “villain” to “hero” in the eyes of many.

At the same time, undercurrents of a war on science came to a boiling point. Spectators and officials began publicly arguing with scientific facts. The lessons learned from this period are messy and contradictory, and it remains to be seen whether in years to come the pandemic will have served as a rallying point around the triumphs of science, or a further solidification of a dividing line between its advocates and disbelievers. If 2020 was about reaction and 2021 about action, 2022 will be a year of picking up the pieces to create a stronger, more unified force that is better equipped to confront large-scale public health crises that the future holds in store.

Image courtesy of Syngene

Next:

Interview: Janssen Pharmaceuticals